It is now well accepted that pathologies occurring at adult age have to be considered not only as consequences of adult events, but also as related to early events in life (ie during pregnancy or early childhood). Therefore, the general idea of our project is to determine the impacts of early exposome (in utero, kids up to 5 years old) on the onset of events (low birth weight, preterm birth, bronchopulmonary dysplasia, …) that constitute susceptibility factors to develop lung disease at adult age (such as chronic obstructive pulmonary disease - COPD), or to impact the course of genetic disease such as cystic fibrosis (CF). In the term "exposome", will be evaluated mainly air pollution, but also the noise, climate, life style (sports, …), socio-economic status, light exposure, air conditioning at home/work, … The project will use already constituted cohorts (pregnant mother and kids, from the general population, and from CF-constituted cohorts). On these cohorts, beside a thorough characterization of the exposome as well as clinical parameters, we will look for new biomarkers of exposome (focus on lipidomic and epigenetic analysis) to be linked with the onset of susceptibility factor, and develop a sensor based on these biomarkers. The relevance of the clinical findings will be addressed thanks to preclinical models exposed to simulated atmospheres ± noise, climate change, exercise, … The use of simulation chambers in a biological context constitutes a major innovative aspect of our project, as no such experimental set-up has been built before, and has therefore never been proposed in EU project focused on exposome. Risk assessment will be performed (multicriteria risk assessment and machine learning implementation), as well as economic evaluation (cost effectiveness and econometric modeling). Overall, the project should lead to new guidelines and recommendations regarding exposome/health effects. These could be beneficial to clinicians (to identify individuals at risk), researchers (to develop future treatments), and to public (to assess their personal risk, hopefully leading to changes of lifestyle). The production of several patents can be envisioned in the frame work of the project following the identification of new biomarkers and the development of sensors. To achieve our aim, the proposed network has a clear multidisciplinary dimension, as it brings together expertise of epidemiologists (Danish Cancer Society Research Center), adult and pediatrician lung specialists (CHI Créteil), physico-chemist of the atmosphere (LISA, FORTH), biologists (IMRB, Lipotype, Cambridge Epigenetix), engineer for sensor development (Fraunhofer), economics (Data Mining International), ethics and legal issues specialists (LN). The actual consortium will be completed with 2 other cohorts of patients (partners currently under discussion: ALSPAC, UK and RHINESSA, NO), and at least one partner for the dissemination of guidelines and recommendation (partner to be found).

We aim at constituting a platform for exploiting complementary competences in material science, physics of condensed matter, nanotechnology and photonics for the design, investigation, fabrication and assessment of transparent glass-ceramics based photonic devices finding application in ICT, environment, space, sensing and health. The tailored materials and devices are intended to boost both basic and applied research through innovation in synthesis, measurements, modelling and applications. The network will be a powerful instrument to associate industrial and academic scientists with fundamental and applied science expertise, from complementary disciplines such as physics, chemistry and engineering, interconnecting all of them focusing on the glass-ceramics exploitation chain from the material synthesis to the device fabrication at TRL 4. We plan to establish an original and flexible system to nucleate new concepts and new technologies in glass photonics on the basis of the already consolidated European competences. We have in mind a platform to promote specific networking for an application at the ITN call. The interdisciplinary competences present in this network certainly allow to be exploited in European outreach project to promote transparent glass-ceramics based technologies. The tackled subjects in the framework of this network will have to enhance the growth of technological and scientific competences in the area of glass-ceramics as well as the capability of transferring innovation to the market. We are confident that during the first months of activity, the network will be able to identify breakthrough demands (topics) attracting new productive and excellent scientific stakeholders. The competence sphere of the network activity concerns glassy nanocomposites derived fibres, waveguides, microresonators, microcavities and photonic crystal opals. These structures, when doped by, e.g., metallic nano-objects or nanocrystals activated by rare-earth ions, are very effective for the development of different photonic and optronic devices with specific functionalities covering a broad range, from civil infrastructure, security and environmental protection sensors to solar energy exploitation, from quantum optics devices, to light sources for health care, lighting and manufacturing. We expect solid and reliable foreground and sideground outcomes. We strongly believe that this platform has a solid background and a clear vision of the way to combine advancement of knowledge and technological transfer, with the capability of attracting other partners and of allowing direct application of H2020 goals.

OpenBar is a European infrastructure for supporting and assisting Medtech companies, including start-ups and SMEs, in their development of innovative medical devices. OpenBar offers support from the stage of proof of concept at the laboratory scale (TRL4) until the submission of the regulatory dossier to the notified body. This accompaniment includes the design consultancy, the regulatory tests foreseen in the new European regulatory framework MDR and IVDR, the preparation of the scale up manufacturing, the techno-economic studies and the support for industrial development. Medical devices analyzed by OpenBar should be ready for the submission of their regulatory dossier (TRL7) prior to market access. The objective of OpenBar is to reduce the costs and times of development of medical devices and of their regulatory approval. OpenBar is positioned upstream to the CRO (Contract Research Organisations) and the Notified Bodies, with which it collaborates. OpenBar has the ambition to serve any European company of any size, developing innovative medical devices in the field of in vitro diagnostics (IVDM), Active implanted devices (AIMD) and non-active devices (NAMD). It is associated with a large network of partners associated with the 15 European Medtech clusters and 5 professional unions. In parallel with its mission of supporting medtech companies, OpenBar is also developing a programme for the development, validation and even standardization of new tests for the evaluation of the safety of medical devices to meet the new requirements imposed by the two new European directives MDR and IVDR. These include studies of biocompatibility, clinical efficacy, usability (human factor), medical software and the management of personal health data. OpenBar offers a unique European entry point to a range of scientific, technical, economic and regulatory competences in the field of innovative medical devices, served by a consortium composed of the 4 largest Research and Technology Organisations, University Hospitals, universities, private companies, SMEs, investors and consultants. This unique set of partners specializing in the development and the market access of innovative medical devices offers access to its infrastructure of testing and development laboratories, centers of pre-clinical and clinical studies. OpenBar aims to become a sustainable organisation beyond the European funding period. A business plan will be delivered at the end of the project.

Cancer registries collect, store, and analyse information about tumor diseases to allow researchers to evaluate the effectiveness of therapies and discover environmental factors influencing certain cancer types. The data processing architecture of cancer registries in France and Germany was initially proposed in the nineties when neither the concept of privacy has been formalised at the level as it is today, nor did mobile apps and cloud services exist. Since then, legislation in Germany (KFRG as of 2013) and Europe (EU-GDPR as of 2018) has developed and data protection requirements are much clearer on the one hand, while the authority of cancer registries to analyse data has been extended. However, cancer registries in Germany and France face ongoing challenges in supporting detailed data analytics in an evolving market of mobile apps and cloud services, while protecting critical personal and health data. They are still organised as mostly isolated data silos and although they stick to common data schemes (e.g. the ADT/GEKID-Basic Record), it is still not possible to query more than a single registry at a time. As both countries face the same challenges in this area and complementing research expertise is available in France and Germany likewise, UPCARE aims at joining these forces to create a modern infrastructure for an overarching cancer registry query platform that complies with existing data schemas and protocol specifications, but leverages recent advances in the field of privacy-preserving computation and pairing-based cryptography. Specifically, UPCARE will: - allow registry-spanning queries for legitimate cancer researchers - keep users in the loop and let them provide informed consent to usage of their data. UPCARE will develop a novel Attribute-Based Encryption (ABE) scheme supporting purpose-bound access schemes. - Provide private computing services for anonymised statistical analyses via a public API. To this end, UPCARE will combine homomorphic encryption solutions with differential privacy to achieve a quantifiable privacy level over encrypted data. - Combine the above research advances in an architecture to make all data records inaccessible to the platform itself, so a breach of the overall query platform will not impact the privacy of any patient. These features do not exist up to date but will become highly relevant as recent legislation in Germany fosters mobile apps and online services to process existing health data, provided that personal data is protected. By combining their closely related, yet not fully overlapping research topics, both French and German project partners will benefit from an exchange of ideas and people during the project in the form of project meetings and occasional research visits. Impact on future society: UPCARE aims to overcome the current isolation of cancer registry databases to enable researchers to conduct cross-national studies while preserving the autonomy of the individual cancer registries and protecting the patient’s privacy. It will be the first multi-national cancer research platform. At a political level, it will demonstrate that data minimisation is not the only way to achieve data protection, but that also smart cryptographic approaches can be used to achieve both, data protection and analytics.